Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vermillion Appoints SVP of Sales and Marketing and Chief Commercial Officer

Published: Friday, December 20, 2013
Last Updated: Friday, December 20, 2013
Bookmark and Share
Appointment of Marian E. Sacco as senior vice president of sales and marketing.

Vermillion, Inc. has appointed Marian E. Sacco as senior vice president of sales and marketing and chief commercial officer.

Ms. Sacco is a proven leader in launching and building markets for innovative diagnostics to address key issues in improving women's health. She has more than 25 years of experience in product development, worldwide marketing, operations and sales management in both private and public companies.

Her focus on women's health began at Centocor Diagnostics where her achievements include the U.S. launch of CA125 used to monitor ovarian cancer recurrence.

More recently, she successfully led the commercial effort to build the global product market and laboratory service business for novel tests to manage pregnancy risks and infertility diagnostics as senior vice president, sales and marketing at Adeza BioMedical (acquired by Cytyc Corporation for more than $450 million, now part of Hologic).

"We are excited to add Marian's experience, energy and expertise in women's health and oncology to our team, as Vermillion expands its leadership role in commercializing OVA1 and future diagnostic tests," said Tom McLain, Vermillion's president and chief executive officer. "Marian has worked with us as a consultant in developing our commercial strategy. In this new role, she will draw on her proven track record in developing and executing sales and marketing strategies to expand awareness with physicians, patients and healthcare providers and drive increased use of OVA1."

Immediately prior to joining Vermillion, Ms. Sacco worked with numerous women's healthcare companies as a strategy and commercialization consultant. Her clients included both product and laboratory service companies focused on new, novel tests and technologies in genetics, pregnancy, reproductive health and oncology.

While at Adeza, Ms. Sacco oversaw both the strategic and day-to-day leadership of a global sales and marketing organization of more than 120 people. Over a 10-year period, her organization grew annual revenues from $1 million to $60 million and built the market for a unique test to aid in the management of preterm births.

By working with clinical thought leaders, gynecologists, nurses and health plans, she and her team successfully demonstrated that this test was clinically relevant, evidence based and cost effective and improved patient outcomes. This effort led to the introduction of new patient care guidelines in leading healthcare institutions, a critical step in building adoption, utilization and reimbursement.

Prior to Adeza, Ms. Sacco worked in senior commercial management roles at Behring Diagnostics, Chiron Diagnostics, and Ciba Corning Diagnostics. During this period, she developed and implemented novel oncology strategies including the launch of "companion diagnostics" in partnership with pharmaceutical business units.

Early in her career at Centocor Diagnostics, she managed U.S. sales, marketing and customer service for innovative cancer tests including launches of CA125, as well as CA15-3 for breast cancer monitoring.

Ms. Sacco holds a Master's degree in Radiopharmaceutical Science from Northeastern University and a Bachelors of Science degree in Chemistry/Biology from Marietta College.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Friday, March 21, 2014
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Company will next pursue a national price for its OVA1 test in 2014.
Saturday, March 08, 2014
Vermillion to Present at the 26th Annual ROTH Conference
Company to present at the conference on March 11, 2014.
Thursday, March 06, 2014
Vermillion to Present at Leerink Global Healthcare Conference
Conference to be held at the Waldorf Astoria Hotel from February 12-13, 2014.
Tuesday, February 04, 2014
Vermillion Completes $17.6 Million Warrant Exercise
Proceeds from the warrant exercise will be used to increase test sales for OVA1.
Friday, December 20, 2013
Vermillion Reports Results of 2013 Annual Meeting
Company has approved the reappointment of Peter S. Roddy.
Friday, December 20, 2013
Vermillion Board of Directors Elects James T. LaFrance as Chairman
LaFrance has been appointed a member of Company’s board on December 12, 2013.
Monday, December 16, 2013
Vermillion Reports Third Quarter 2013 Results
Company reports Q3 2013 financial results and key developments.
Friday, November 15, 2013
American Journal of Obstetrics & Gynecology Publishes New Clinical Study of OVA1 Test
Significantly superior early-stage sensitivity shown versus CA125, modified ACOG guidelines or overall clinical assessment in premenopausal and postmenopausal women planning surgery.
Thursday, November 14, 2013
Vermillion Appoints Dr. Eric Varma to its Board of Directors
Dr. Varma is currently a partner at Oracle Investment Management.
Tuesday, September 17, 2013
Vermillion's OVA1 Receives New Statement by SGO
OVA1® has received new statement on clinical validation and medical use.
Tuesday, July 16, 2013
Vermillion Appoints President and Chief Executive Officer
Appointment of Thomas McLain effective March 18, 2013.
Thursday, July 04, 2013
Vermillion Appoints Bruce A. Huebner to Chairman of the Board
Shareholders to vote on approval of expanded stock incentive plan at upcoming annual meeting.
Friday, June 28, 2013
Vermillion Announces Closing of Equity Financing
Company to increase the number of directors of the Company from six to eight persons.
Thursday, May 16, 2013
Vermillion Supports First World Ovarian Cancer Day
Vermillion offers women new hope with OVA1, a FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass.
Thursday, May 16, 2013
Scientific News
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!